Kymera Perspectives
Hear from our team on recent breakthroughs, scientific and clinical advancements, company culture, and our ongoing work to develop new medicines at Kymera.
October 28, 2024
STAT6 Degradation: A Paradigm Shift in Immunology
KT-621 is the first oral STAT6 targeted medicine to advance into the clinic, and we believe KT-621 can provide the convenience of a once daily oral pill with the potential to deliver biologics-like activity for patients suffering from highly prevalent allergic and atopic diseases around the world. Hear from our CEO, Nello Mainolfi, as he discusses the origin and opportunity of this milestone moment and what it means for patients.
Featured
March 31, 2023
Driving Culture Through Values
Karen Weisbach, PHR, Head of People + Culture
March 1, 2023
Living Our Core Values – Pioneer: Breaking new ground with a powerful new modality
Juliet Williams, PhD, Head of Research
April 21, 2023
Small Molecules, Big Impact: Expanding the Universe of Targets
Brian Albarran, PhD, Senior Vice President, Head of Corporate Strategy
Discover Our Latest Milestones
Stay ahead with the latest news from Kymera. Our Press Releases provide insights into our recent achievements and future endeavors.
Related Stories
